In summary, high expressions of SPNS2 and SPNS3 can indicate adverse prognosis in chemotherapy AML patients, and the prognosis effect of SPNS2 can be overcome by allo-HSCT, and they might be used as predictors for AML patients in the future. The gene discussed is SPNS3; the disease is acute myeloid leukemia.